Luminal breast cancer: from biology to treatment

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement†

(2013) H. A. Azim et al.   ANNALS OF ONCOLOGY

42O_PR * ASSESSMENT OF GENETIC ALTERATIONS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FROM THE BOLERO-2 TRIAL BY NEXT-GENERATION SEQUENCING

(2013) M. Piccart et al.   ANNALS OF ONCOLOGY

53O_PR * PREDICTING RISK FOR LATE METASTASIS: THE PAM50 RISK OF RECURRENCE (ROR) SCORE AFTER 5 YEARS OF ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH HR+ EARLY BREAST CANCER: A STUDY ON 1,478 PATIENTS FROM THE ABCSG-8 TRIAL

(2013) M. Gnant et al.   ANNALS OF ONCOLOGY

54O_PR * COMPARISON OF FIVE DIFFERENT SCORES FOR THE PREDICTION OF LATE RECURRENCE FOR OESTROGEN RECEPTOR-POSITIVE BREAST CANCER

(2013) I. Sestak et al.   ANNALS OF ONCOLOGY

European cancer mortality predictions for the year 2013

(2013) M. Malvezzi et al.   ANNALS OF ONCOLOGY

HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab

(2013) S. Ithimakin et al.   CANCER RESEARCH

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer

(2013) Sherene Loi et al.   JNCI-Journal of the National Cancer Institute

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

(2013)   LANCET

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

(2013) Muhammed Murtaza et al.   NATURE

Emerging targeted agents in metastatic breast cancer

(2013) Dimitrios Zardavas et al.   Nature Reviews Clinical Oncology

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013) Sarah-Jane Dawson et al.   NEW ENGLAND JOURNAL OF MEDICINE

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

(2013) Sherene Loi et al.   PLoS One

The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap

(2013) Matthew J. Ellis et al.   Cancer Discovery

Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives

(2013) Maria Vittoria Dieci et al.   Cancer Discovery

Liquid biopsy to test new treatment strategies in breast cancer: are we there yet?

(2012) M. Ignatiadis et al.   ANNALS OF ONCOLOGY

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

(2012) P. Dubsky et al.   ANNALS OF ONCOLOGY

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study

(2012) V. Georgoulias et al.   ANNALS OF ONCOLOGY

Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients

(2012) E.- F. Solomayer et al.   ANNALS OF ONCOLOGY

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

(2012) P. E. Goss et al.   ANNALS OF ONCOLOGY

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

(2012) R. Coleman et al.   ANNALS OF ONCOLOGY

Abstract 5054: Inferring mutational chronology in breast cancer by deep-sequencing tumor subpopulations

(2012) Nicholas E. Navin et al.   CANCER RESEARCH

Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398in vitro

(2012) Richard S. Finn et al.   CANCER RESEARCH

Mutational Processes Molding the Genomes of 21 Breast Cancers

(2012) Serena Nik-Zainal et al.   CELL

The Life History of 21 Breast Cancers

(2012) Serena Nik-Zainal et al.   CELL

Circulating Tumor Cells--New Challenges Ahead

(2012) E. S. Lianidou   CLINICAL CHEMISTRY

Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)

(2012) K. Johnston et al.   EUROPEAN JOURNAL OF CANCER

Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

(2012) Himisha Beltran et al.   EUROPEAN UROLOGY

FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer

(2012) Jonas Bergh et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

(2012) Thomas Bachelot et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression

(2012) Linda Sofie Lindström et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis

(2012) Michail Ignatiadis et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

(2012) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Bone-Targeted Agents on Cancer Progression and Mortality

(2012) R. Coleman et al.   JNCI-Journal of the National Cancer Institute

A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes

(2012) Benjamin Haibe-Kains et al.   JNCI-Journal of the National Cancer Institute

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Bisphosphonates in early breast cancer

(2012) Peter Dubsky et al.   LANCET ONCOLOGY

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial

(2012) Alexander HG Paterson et al.   LANCET ONCOLOGY

Circulating tumour cells in non-metastatic breast cancer: a prospective study

(2012) Anthony Lucci et al.   LANCET ONCOLOGY

Sequence analysis of mutations and translocations across breast cancer subtypes

(2012) Shantanu Banerji et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Molecular prescreening to select patient population in early clinical trials

(2012) Jordi Rodón et al.   Nature Reviews Clinical Oncology

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Evolution of the cancer genome

(2012) Lucy R. Yates et al.   NATURE REVIEWS GENETICS

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer

(2012) Rita S. Mehta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

Whole-Genome Sequencing and Cancer Therapy: Is Too Much Ever Enough?: Figure 1.

(2012) Levi A. Garraway et al.   Cancer Discovery

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2011) F. Cardoso et al.   ANNALS OF ONCOLOGY

Outcome of special types of luminal breast cancer

(2011) M. Colleoni et al.   ANNALS OF ONCOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Genetic Interactions in Cancer Progression and Treatment

(2011) Alan Ashworth et al.   CELL

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

(2011) Martin Filipits et al.   CLINICAL CANCER RESEARCH

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

(2011) Emiel Rutgers et al.   EUROPEAN JOURNAL OF CANCER

Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?

(2011) Fabrice Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

(2011) M. Dowsett et al.   JNCI-Journal of the National Cancer Institute

Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors

(2011) E. Vilar et al.   MOLECULAR CANCER THERAPEUTICS

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

(2011) Robert E. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Controversies in clinical cancer dormancy

(2011) J. W. Uhr et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

(2011) S. Roychowdhury et al.   Science Translational Medicine

Toward Molecular Imaging–Driven Drug Development in Oncology: Figure 1.

(2011) Elisabeth G.E. de Vries et al.   Cancer Discovery

Biology of breast cancer bone metastasis

(2010) Mojtaba Akhtari et al.   CANCER BIOLOGY & THERAPY

FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

(2010) N. Turner et al.   CANCER RESEARCH

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic Testing in Li-Fraumeni Syndrome: Uptake and Psychosocial Consequences

(2010) Chantal R.M. Lammens et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

(2010) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome

(2010) Heinz-Josef Klümpen et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

(2010) Britta Weigelt et al.   LANCET ONCOLOGY

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

(2010) Rebecca Aft et al.   LANCET ONCOLOGY

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

(2010) S. Loi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

(2009) F.-C. Bidard et al.   ANNALS OF ONCOLOGY

PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer

(2009) R. J. Crowder et al.   CANCER RESEARCH

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

(2009) Steven M Teutsch et al.   GENETICS IN MEDICINE

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

(2009) Kathy S Albain et al.   LANCET ONCOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene-Expression Signatures in Breast Cancer

(2009) Christos Sotiriou et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer

(2008) X.-J. Ma et al.   CLINICAL CANCER RESEARCH

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

(2008) C. Desmedt et al.   CLINICAL CANCER RESEARCH

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

(2008) Eleftherios P. Mamounas et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

(2008) Soonmyung Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE